Central nervous system complications after combination treatment with adriamycin (NSC-123127) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).
D000328:Adult; D000577:Amides / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects* / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination / Q000009:adverse effects; D004828:Epilepsies, Partial / Q000139:chemically induced; D004830:Epilepsy, Tonic-Clonic / Q000139:chemically induced; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D012509:Sarcoma / Q000188:drug therapy; D012640:Seizures / Q000139:chemically induced*; D014226:Triazenes / Q000009:adverse effects* / Q000627:therapeutic use
D000577:Amides; D000970:Antineoplastic Agents; D007093:Imidazoles; D014226:Triazenes; D004317:Doxorubicin